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The pathogenesis of Parkinson’s disease (PD) seems to involve genetic susceptibility to neurodegeneration. APOE gene has been
considered a risk factor for PD. This study aimed to evaluate the association of APOE polymorphism with PD and its influence on
lipid profile. We studied 232 PD patients (PD) and 169 individuals without the disease.The studied polymorphism was analyzed by
PCR/RFLP.The Fisher’s exact test, chi-square, ANOVA, and 𝑡-test (𝑃 < 0.05) were applied.TheAPOE3/3 genotype was prevalent in
PD patients andControls (𝑃 = 0.713) followed byAPOE3/4 (𝑃 = 0.772). Both groups showed recommended values for lipid profile,
with increase in the values of total cholesterol and LDLc, as well as decreased values of triglycerides in PD patients compared with
Controls (𝑃 < 0.05 for all of them). Increased levels of HDLc, in PD patients, were associated with the APOE3/3 versus APOE-/4
genotypes (𝑃 = 0.012). The APOE polymorphism does not distinguish PD patients from Controls, as opposed to the lipid profile
alone or in association with APOE. Furthermore, a relationship between increase of HDLc levels and APOE3 in homozygous was
found in PD patients only.
1. Introduction
Parkinson’s disease (PD) is a complex neurodegenerative
disorder, chronic and progressive, affecting 2% of the pop-
ulation older than 65 years [1]. The identification of specific
biomarkers for PD is one of the main goals of this clinical
research. Today the diagnosis of this second most common
neurological disease is possible by clinical evaluation of
extrapyramidal signs, such as tremor, rigidity, and bradyki-
nesia. These symptoms occur when the degeneration of
nigral dopaminergic neurons of substantia nigra (SN), which
project to the striatum [1], disrupting the motor circuit of the
basal ganglia, has risen over 70% [2–4]. It has been suggested
that cognitive deficit is a common feature of PD [1].
In Brazil, the incidence of PD is equivalent to 150/200
cases per 100,000 inhabitants, with the emergence of
20/100,000 new cases per year [5]. The etiology of PD seems
to involve genetic susceptibility and environmental factors
[6]. Some evidence shows that mitochondrial dysfunction,
oxidative stress, and genetic factors play an important role in
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the pathogenesis of this disease [7]. Approximately 85%of PD
cases are sporadic, 10–15% of patients have family history, and
less than 5% of them present monogenic inheritance [8].
The apolipoprotein E (ApoE) plays an important role in
the lipoprotein metabolism [9] and transport of lipids to tis-
sues [10]. It serves as a ligand for at least two specific receptors
of lipoproteins, the low density lipoprotein receptor (LDLr)
or ApoB/E and the liver receptor to apoE, the lipoprotein
receptor-related proteins (LRP = LDL receptor related pro-
tein), allowing the removal of these particles by the liver [11].
The apolipoprotein E (ApoE) is also the main apolipoprotein
in the central nervous system, with evidence of its association
with cerebrovascular diseases [12], and neurodegenerative
diseases as late onset of Alzheimer’s Disease (AD) [13, 14] and
PD [15, 16]. Thus, APOE gene has become a significant target
for investigation in neurodegenerative diseases.
The APOE gene, containing four exons, is mapped on the
human chromosome 19q13.2 [17]. The APOE polymorphism,
located on exon 4, is identified in the form of three major
alleles APOE2 (prevalence of 0.01 to 0.15), APOE3 (0.49 to
0.91), and APOE4 (0.06 to 0.37) [18], which determines three
protein isoforms (E2, E3, and E4, resp.) and six possible
genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, and e4/e4). E2
and E3 clear plaques 20 timesmore efficiently than E4 [19]. E3
seems to be the normal isoform in all known functions, while
E4 and E2 can each be dysfunctional [19]. Some researches
and a meta-analysis study have shown that the e2 allele
is associated with higher risk of PD development [18, 20,
21], whereas other studies have shown that the e4 allele is
responsible for PD development [15, 21–23]. Therefore, both
the e2 and the e4 alleles may play a role in PD development.
APOE is responsible for clearance of the b-amyloid plaques
which impair the nervous system [24].Therefore, the APOE4
allele is associated with high concentrations of LDLc and
APOE2 at low plasma levels of LDLc [25]. The apoE is
synthesized by astrocytes within the brain, and among its
polymorphisms, the APOE4 allele, in particular, seems to
have a risk effect on PD and a possible relationship with
the existing neurodegeneration among Parkinson’s disease
patients. Some studies have considered 𝜀4 as a risk factor
for the age of onset for PD, decline in cognitive impairment,
and/or development of dementia in PD.APOE2 has also been
identified as an important risk factor for PD, however, with
weak and inconsistent effect across studies [1, 26–34].
Therefore, the change in lipid metabolism mediated by
different isoforms of apoE could influence the neuronal
degenerative processes. Several mechanisms have been pro-
posed associating increased risk of PD development with
higher plasma levels of total cholesterol (TC) [35]. However,
only a few case-control studies [36, 37] and a few prospective
epidemiological findings [38, 39] evaluated such association
but with no conclusive results. In this case, prospective
studies showing reduced risk of PD with increased plasma
levels of TC were highlighted [35, 38].
In accordancewith themultifactorial etiologic hypothesis
for PD susceptibility genes, even though modest, may have
an association with the disease [18].Thus, this study aimed to
evaluate the association among polymorphisms ofAPOE and
PD, and to provide a comparative analysis of lipid profile in
different ApoE genotypes in patients with PD and individuals
without the disease.
2. Methods
This is a randomized case-control study performed with
individuals (𝑁 = 401) with mixed ethnicity [40]. They were
divided into PD patients: 232 patients with PD, mean age =
69.2 ± 11.1 years and 62% male and Controls: 169 individuals
not diagnosed with PD, mean age = 71.7 ± 8.5 years and
48% male. Patients were selected at the Movement Disorders
Clinic of the Hospital de Base of Sao Jose do Rio Preto
Medical School, SP, Brazil. The diagnosis of PD was per-
formed by a neurologist specializing in movement disorders,
who applied the clinical criteria recommended by Jankovic
[2], including bradykinesia, rigidity, tremor at rest, postural
instability, unilateral onset, response to L-dopa for more than
5 years, levodopa-induced dyskinesia, progressive disorder,
persistent asymmetry and clinical course of 10 years or more,
and complementary tests [2]. In the diagnosis of PD, we
included at least one neuroimaging method (skull PET, MRI,
or cerebral scintigraphy by SPECT). Healthy individuals
(Controls) were treated by other specialists of the same
treatment unit and had the same age as those patients selected
in the PD group. Those individuals under hypolipidemic
drug therapy and/or any specific diet were excluded from
both groups. All subjects were informed about the nature
of the study and confirmed their willingness to participate
by signing written consent forms. This study was approved
by the Ethics Research Committee of the institution (opin-
ion/no. 151/2008—Certificate of Appreciation Presentation
Ethics (CAAE) 0029.0.140.000-08).
Peripheral blood was collected in order to obtain anal-
ysis of genetic polymorphisms for APOE and lipid profile,
including plasma levels of total cholesterol (TC), low den-
sity lipoprotein cholesterol (LDLc), high density lipoprotein
cholesterol (HDLc) and very low density (VLDLc), and
triglycerides (TG). Lipid profile tests were partially done
for the PD patients (𝑁 = 86) as it was difficult to collect
enough biological material (peripheral blood) for all analyses
(genetic and biochemical).The study ofAPOE polymorphism
(rs429358 and rs7412) was performed in the Center for
Research in Biochemistry and Molecular Biology of Sao
Jose do Rio Preto Medical School and consisted of genomic
DNA extraction from whole blood samples (5mL) [41] and
DNA amplification by conventional PCR (polymerase chain
reaction) and enzymatic restriction (Hha I).
Each reaction was performed in Eppendorf-Mastercycler
thermocycler; each tube contained 0.5 𝜇L of nucleotides
(0.8mM), 2.5 𝜇L of buffer PCR 10X, 2.5 𝜇L of dimethyl
sulfoxide 10%, 2.5𝜇L of each primer (2.5𝜇M), 0.2𝜇L of
Taq polymerase (5U/𝜇L), 11 𝜇L of Milli Q water, and 2𝜇L
of diluted genomic DNA (0.2 𝜇g). Complementary primers
were used in regions next to the polymorphic codons 112 and
158, located in exon 4 of APOE (rs429358 and rs7412) P1: 5󸀠-
ACA GAA TTC GCC CGG CCT GGT ACA C-3󸀠 and P2: 5󸀠-
TAA GCT TGG CACGGC TGT CCAAGCA-3󸀠 [42]. Initial
DNA denaturation was obtained at 94∘C during 5 minutes,
and the reaction mix submitted to 40 cycles of 94∘C during
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Table 1: Distribution of absolute and relative frequencies of alleles
and genotypes of APOE polymorphism in individuals with Parkin-
son’s disease (PD) and without (Controls).
Genotype
APOE
PD (𝑁 = 232) Controls (𝑁 = 137) P∗
N % N %
Genotype
APOE2/4 1 0.4 0 — —
APOE2/3 19 8.1 8 5.8 0.535
APOE3/3 169 73.0 103 75.2 0.713
APOE3/4 37 15.9 24 17.5 0.772
APOE4/4 6 2.6 2 1.5 0.727
Total 232 100 137 100
APOE-/4 44 18.9 26 18.9 1.000
APOE-/2 20 8.6 8 5.8 0.413
Allele
APOE2 20 0.04 8 0.03 0.426
APOE3 394 0.85 238 0.87 0.515
APOE4 50 0.11 28 0.10 0.901
Total 464 1.0 274 1.0
∗Fisher or Chi-squared tests; N: total number of individuals; Abs. Freq.:
absolute frequency.
30 seconds and 65∘C during 2 minutes, extension at 72∘C
during 1 minute, and ending cycle at 72∘C during 7 minutes
[42].
The analysis of ApoE genetic variants was performed by
restriction fragment length polymorphism (RFLP) analysis,
with the restriction enzymeHha I fast (5U per reaction tube)
in double boiler at 37∘C during 45 minutes, for cleavage of
amplified sequences in specific regions (GCGC), identifying
the alleles APOE2, APOE3, and APOE4. The DNA fragments
were separated by electrophoresis on 6% polyacrylamide
gel nondenatured, under constant electric current of 180V
during 2 hours. A standardDNA sample (100 base pairs, Invi-
trogen) was used as comparison with the electrophoretic
bands of patients.The gel was colored by GelRed (Uniscience
of Brazil) during 10 minutes, and DNA fragments were
visualized under ultraviolet light (UV).
3. Statistical Analysis
Categorical variables (including demographic data and
genetic variants) were analyzed applying Fisher’s exact test
and the Chi-square test. Continuous variables (age, values
for lipid profile) were analyzed by ANOVA, Tukey, 𝑡-test, or
Mann-Whitney test. 𝑃 < 0.05 was considered statistically
significant. Statistical analysis also included Hardy-Weinberg
equilibrium (Fisher’s exact test and the Chi-square test).
4. Results
Table 1 shows the genotype distribution and allele frequencies
of the APOE polymorphism. We observed the prevalence
of APOE3/3 genotype in PD patients (73.0%) and Controls
(75.2%, 𝑃 = 0.713), followed byAPOE3/4 (15.9%, 17.5%, resp.;
Table 2: Distribution of means and standard deviation for lipid







(𝑁 = 169) P
∗
TC
Mean 202.5 186.8 0.017
SD 45.7 51.1
HDLc
Mean 58.0 56.8 0.574
SD 13.2 20.9
LDLc
Mean 122.0 102.8 0.001
SD 38.7 44.9
VLDLc
Mean 22.8 31.3 0.001
SD 13.3 29.4
TG
Mean 115.5 136.9 0.024
SD 66.7 73.5
∗t-test; TC: total cholesterol; HDLc: high density lipoprotein cholesterol;
LDLc: low density lipoprotein cholesterol; VLDLc: very low density lipopro-
tein cholesterol; TG: triglycerides; SD: standard deviation; N: number of
individuals.
𝑃 = 0.772). There was a similar distribution of alleles of the
ApoE in both groups (𝑃 > 0.05).
Concerning the lipid profile (Table 2), both groups
showed values within the reference limits of normality, except
for patients with slightly increased TC mean value (202.5 ±
45.7mg/dL). This group showed higher TC and LDLc levels
(122.0 ± 38.7mg/dL) and lower VLDLc and TG levels (22.8
± 13.3mg/dL, 115.5 ± 66.7mg/dL, resp.), compared with
Controls (186.8 ± 51.1mg/dL; 𝑃 = 0.017; 102.8 ± 44.9mg/dL;
𝑃 = 0.001; 31.3 ± 29.4mg/dL; 𝑃 = 0.001; 136.9 ± 73.5mg/dL;
𝑃 = 0.024, resp.).
Table 3 shows the relationship between lipid profile and
APOE polymorphism. PD patients present a relationship
between APOE-/4 and a decrease in HDLc levels (51.8 ±
10.5mg/dL), compared with APOE3/3 (60.3 ± 13.3mg/dL;
𝑃 = 0.025). Furthermore, patients with APOE3/3 geno-
type showed significantly higher levels of HDLc (60.3 ±
13.3mg/dL) and reduced levels of VLDLc and TG (22.7 ±
13.1mg/dL; 113 ± 65.7mg/dL, resp.), compared with Controls
with the same genotype (52.0 ± 15.5mg/dL; 𝑃 = 0.001; 36.6 ±
37.4mg/dL; 𝑃 = 0.001; 143.5 ± 79.8mg/dL; 𝑃 = 0.017, resp.).
In Controls, individuals with APOE3/3 genotype presented
higher values of VLDLc, compared with those with APOE-/4
genotypes (𝑃 = 0.002).
5. Discussion
This study shows similar genotype distribution and allele
frequency for the APOE polymorphism in PD patients and
Controls, as described by other authors [1, 25–28]. On
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Table 3: Means and standard deviations for lipid profile in patients with Parkinson’s disease (PD) and without (Controls) considering APOE
polymorphism.










Mean 206.5 203.7 200.7 190.4 0.391∗
SD 48.7 47.4 59.4 54.5
LDLc
Mean 128.7 121.7 123.1 109.9 0.254∗
SD 43.3 38.8 55.0 46.1
HLDc
Mean 51.8 60.3 56.5 52.0 0.007∗
SD 10.5 13.3 15.9 15.5 (axb 𝑃 = 0.012; bxd 𝑃 = 0.001)†
VLDLc
Mean 24.3 22.7 22.6 36.3 0.024∗
SD 17.1 13.1 9.0 37.4 (cxd 𝑃 = 0.001)†
TG
Mean 126.0 113.3 129.7 143.5 0.039∗
SD 82.5 65.7 83.5 79.8 (bxd 𝑃 = 0.010)†
∗One-Way ANOVA Test; †t-test; TC: total cholesterol; HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; VLDLc: very low
density lipoprotein cholesterol; TG: triglycerides; SD: standard deviation; N: number of individuals.
the other hand, ameta-analysis study highlights the increased
susceptibility to the disease associated with presence of the
APOE2 allele (odds ratio: 1.16; confidence interval 95%: 1.03–
1.31) [43], however, not observed in this study. Differences
among studies may be explained by changes in methodology,
sample size, age of manifestation of the disease, ethnicity, and
other environmental and geographic factors which can be
considered in the analysis of genetic polymorphisms.
ApoE genotype distribution differs among populations.
Eichner et al. [44] reviewed the frequencies of E2, E3, and E4
alleles in different populations and reported that these range
from 0.02 to 0.13 for E2, 0.06 to 0.85 for E3, and 0.11 to 0.31 for
E4. The prevalence of the E4 allele in Brazil is similar to that
observed in other SouthAmerican countrieswith frequencies
between 0.23 and 0.26 [14], except for Chileans with a fre-
quency of 0.40. However, in Controls, the prevalence ranges
between 0.08 and 0.19 [45].These frequencies for the E4 allele
are lower than in populations from the northern hemisphere,
whose frequencies vary between 0.38 and 0.48 [46, 47].
The possible association of apoE and risk of PD has
been widely investigated in different populations. However, it
remains underrepresented in the Brazilian population. Thus,
this is a pioneer study in terms of the distribution of ApoE
genetic polymorphisms and its relationshipwith lipid profiles
in patients with PD, helping understand possible genetic
markers for this disease. Considering the relationship of apoE
and lipid metabolism [48], we also evaluated the lipid profile.
The mean values were within the reference limits except for
TC, with slight increase in PD patients [49], who also showed
increased levels of LDLc and reduction in VLDLc and TG
levels, compared with Controls.
Clinical and subclinical conditions [50, 51] can be asso-
ciated with reduced concentrations of cholesterol (TC, LDLc
and HDLc), as observed in inflammatory diseases [50, 52].
Studies also show changes in lipidmetabolismassociatedwith
neurodegenerative diseases, including Alzheimer’s disease
and PD [53, 54]. In this case, there is reference to reduction in
the synthesis of cholesterol in skin fibroblasts from patients
with PD [55], as well as low values of TC compared with
Controls [35].
In an analysis stratified by gender, Pena et al. [40]
observed a reduction in the risk of PD with increased levels
of TC only in women. In men, only higher values of TC
accounted for reduced risk for PD, compared with men with
lower values of TC. However, de Lau et al. [38] found no
relationship among LDLc concentration, duration of PD, and
use of dopaminergic agents. Therefore, both authors suggest
that the relationship between low levels of LDLc and PD is a
consequence of the disease or its treatment.
Additionally, there is speculation that high levels of TC
raise the risk of PD [36], partly due to the excess of body
weight, as some studies observed a relationship between
excess weight and a higher risk for PD [36, 56]. Also, there
is an inverse association between intake of total fat and
unsaturated fatty acids with risk of PD [57, 58]. Thus, a
number of factors strongly influence the variation of lipid
profile in PD patients, which requires strict criteria to be
applied on the selection of the studied groups.
This study also highlights the clear influence of apoE
polymorphisms and lipid profile between the groups. In this
case, PD patients showed increased HDLc levels, compared
withControls, only in those patients withAPOE3/3 genotype,
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who also showed reduced levels of TG and VLDLc when
compared with Controls. Additionally, only PD patients
showed the relationship between the presence of APOE4 and
reduced serum levels of HDLc, compared with APOE3/3
genotype. Thus, PD patients and Controls show differences
in the combination of lipid profile and the apoE-Hha I
polymorphism. On the other hand, Huang et al. [18] detected
increased risk of PD, associated with reduced plasma levels
of TC related to the allele APOE2. Thus, these controversies
may reflect changes in lifestyle habits, drug treatment, and
medical advice to control the disease, which are aspects to be
investigated in further studies.
Therefore, this study allows us to conclude that APOE
polymorphism does not distinguish PD patients from Con-
trols, as opposed to the lipid profile alone or in association
with APOE. In this case, and increase in TC and LDLc
levels can be observed in PD patients, whereas higher VLDLc
and TG levels are prevalent in Controls. Moreover, only
PD patients show a relationship between increase of HDLc
levels and APOE3 in homozygous. Further studies including
subgroups of patients with and without family history of PD
are needed to clarify the influence of genetic polymorphisms
and their respective mechanisms in PD.
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